Core Viewpoint - The article discusses the characteristics, management strategies, and misconceptions related to eczema, emphasizing the need for tailored approaches based on different demographics and conditions. Group 1: Eczema Characteristics - Eczema presents with varying features depending on the disease stage: acute phase shows red papules with exudation, subacute phase shows darkening redness with scaling, and chronic phase shows thickened, leathery skin with pigmentation [2] - In infants, eczema commonly appears on exposed areas like cheeks and scalp, while in school-aged children, it is often found in flexural areas like the elbows and knees. In the elderly, it typically occurs on the lower legs and hands [2] Group 2: Management Strategies - For infants, a moisturizing strategy is crucial, with studies indicating that using moisturizers at least three times daily can reduce moderate to severe eczema flare-ups by 67% [3] - Medication principles for sensitive areas include using 1% pimecrolimus cream or 0.03% tacrolimus ointment, while mild steroids can be used for acute flare-ups on the body [3] - Elderly patients should use moisturizers containing urea (5%-10%) and avoid long-term use of potent steroids, opting instead for intermittent therapy [6] Group 3: Environmental Considerations - Maintaining a room temperature of 20-22 degrees Celsius and humidity of 50%-60% is recommended for eczema management [5] - Clothing for children should be made of pure cotton, and new clothes should be washed in hot water to remove residual chemicals [5] Group 4: Misconceptions and Risks - Traditional beliefs about "removing dampness and toxins" are challenged by modern medicine, which shows that excessive sweating can damage the skin barrier [7] - The fear of using corticosteroids is addressed, highlighting that when used correctly, the risk of skin atrophy is minimal [8] - Patients are advised against blindly avoiding foods unless a specific allergy is confirmed, and a diverse diet during pregnancy may reduce the risk of allergies in infants [10] Group 5: Importance of Individualized Management - Establishing a management model that focuses on moisturizing, medication to control flare-ups, and avoiding triggers is essential [11] - Keeping a diary to track triggers, medication use, and skin condition can aid healthcare providers in creating personalized treatment plans [11]

Core Viewpoint - The article highlights the seasonal increase in cases of "winged sulfur" or blister beetle dermatitis as temperatures rise, emphasizing the importance of avoiding contact with the beetle to prevent skin reactions [1][2]. Group 1: Health Risks and Symptoms - Blister beetles contain a toxic compound called cantharidin, which can cause dermatitis characterized by linear red spots, pustules, and even ulceration upon contact with skin [2][6]. - The peak incidence of blister beetle dermatitis typically occurs from June to September, with a notable increase in cases during this period [2]. Group 2: Prevention and Treatment - Medical professionals advise against swatting the beetle, as this can increase the affected skin area by 3 to 5 times. Instead, it is recommended to gently brush or blow the beetle away [4][6]. - In case of contact, it is suggested to use adhesive tape to remove any remnants of the beetle and rinse the area with running water for 15 minutes, avoiding alcohol or other home remedies [6][8]. - For symptoms like redness and swelling, a 3% boric acid solution or 0.1% acridine solution can be used for wet compresses, while topical corticosteroids may help with itching [8]. Group 3: Environmental Considerations - Blister beetles thrive in warm, humid environments, particularly after rain or in areas with abundant vegetation, making it advisable to avoid such locations [12]. - Residents in areas with many trees and plants should ensure windows are properly screened to prevent beetles from entering homes, especially at night when they are attracted to light [9][14].

Core Viewpoint - In 2024, the company achieved revenue of 4 billion yuan, a slight year-on-year decline, while net profit attributable to shareholders was significantly impacted by a fine related to sodium dexamethasone sales, with a stable growth in non-recurring net profit [1][2][3] - The impact of centralized procurement on the formulation segment has been largely digested, and new products are continuously being introduced, with expectations for accelerated growth in 2025 [1][4] - Revenue from the raw materials segment declined due to inventory destocking by overseas clients and price decreases, but sales volume remains stable, with a positive outlook for gradual recovery [1][5] Financial Performance - In 2024, the company reported operating revenue of 4.001 billion yuan, a year-on-year decrease of 2.98%, and a net profit attributable to shareholders of 397 million yuan, down 29.46% [2][3] - The non-recurring net profit for 2024 was 549 million yuan, reflecting a year-on-year increase of 2.15% [2][3] - For Q1 2025, the company achieved operating revenue of 1.01 billion yuan, a year-on-year decline of 2.9%, with a net profit of 140 million yuan, down 4.7% [2][3] Formulation Segment - In 2024, the formulation sales revenue reached 2.276 billion yuan, an increase of 8% year-on-year [4] - Key therapeutic areas showed varied performance, with gynecology and family planning sales at 450 million yuan, stable year-on-year; anesthetic muscle relaxants at 160 million yuan, up 55%; respiratory products at 880 million yuan, up 31%; and dermatology products at 230 million yuan, up 19% [4] - The company’s new products are expected to accelerate growth, with significant sales increases in new offerings such as sodium glucosamine injection [4][6] Raw Materials Segment - In 2024, revenue from raw materials and intermediates was 1.55 billion yuan, a year-on-year decline of 13% [5] - The decline was attributed to inventory destocking in the international market and increased competition leading to price drops [5][6] - The company is expected to see a recovery in the raw materials segment as prices stabilize and market share increases [5][6] Expense Analysis - In 2024, the company's sales, management, and R&D expense ratios were 25.84%, 7.74%, and 6.63%, respectively, with slight increases year-on-year [7] - The gross margin improved to 57.49%, up 4.61 percentage points, attributed to the clearing of centralized procurement impacts and operational efficiency [7] - The net profit margin was 10%, significantly impacted by a fine provision of 195 million yuan [7] Future Outlook - The company is expected to achieve stable growth in revenue and profit in 2025, with non-centralized procurement products anticipated to grow steadily [8] - Revenue projections for 2025-2027 are 4.35 billion, 4.81 billion, and 5.48 billion yuan, with year-on-year growth rates of 8.6%, 10.7%, and 13.8% respectively [8]